Luminary Group is pleased to share that our CEO, Klajdi Bega, and Partner, Ted Smith-Carey, will be attending LSI Europe ’25 this September in London. As trusted advisors to VCs, private equity firms, and Nasdaq-listed MedTech companies, we specialize in building world-class executive leadership teams across the global Life Sciences sector. We look forward to reconnecting with clients, friends, and industry peers throughout the week. 📍 JW Marriott Grosvenor House, London 📅 September 7th–11th, 2025 #ExecutiveSearch #LeadershipHiring #MedTech #LifeSciences #PrivateEquity #VentureCapital #LSIEurope25 #LuminaryGroup #TalentStrategy #CRO #Diagnostics #HealthTech #ScaleUpTalent #BoardSearch #HiringExcellence #PartneringForGrowth #GrowthLeadership #NasdaqMedTech #FutureOfMedTech #GlobalExecutiveSearch
About us
Luminary Group is a global executive search and leadership advisory firm exclusively focused on the Life Sciences and Pharmaceutical sectors. We partner with high-growth companies across the investment landscape—from Private Equity and Venture Capital-backed innovators to Nasdaq-listed enterprises—supporting them through critical phases of transformation, value creation, and accelerated expansion. Our clients engage us at strategic inflection points: executing buy-and-build strategies, integrating post-M&A, scaling leadership ahead of an IPO or exit, or restructuring to meet shifting market demands. We begin by identifying, assessing, and appointing proven executive leaders—from CEO, COO, CCO, CPO, CMO, CSO to Director-level roles—who align with your long-term vision and culture. Once the leadership foundation is in place, we work hand-in-hand with our clients to build out high-performing teams and business units across key functions, including Business Development, Commercial, Medical, Engineering, Operations, Technology, HR and Finance. This end-to-end partnership is designed to increase the likelihood of achieving your business goals—whether that’s preparing for a successful exit, scaling ahead of IPO, or driving sustained global growth. Our sector expertise spans CDMO, CRO, Medical Devices, Biotech, Healthcare Technology, Artificial Intelligence, Consulting, and finally, Real World Evidence and eClinical Solutions. We bring localized insight, a global talent network, and a consultative, data-informed approach to every engagement. At Luminary Group, your goals are our goals. Whether you're preparing for an exit or launching into public markets, we build leadership teams that are built to deliver—today and for the long term.
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Executive Search Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
Get directions
City of London , GB
-
Get directions
Dso - IFZA, IFZA Properties
Dubai , Dubai Oasis Silico, AE
Employees at Luminary Group
Updates
-
𝗝𝗮𝘇𝘇'𝘀 𝗠𝗼𝗱𝗲𝘆𝘀𝗼 𝗯𝗲𝗰𝗼𝗺𝗲𝘀 𝗳𝗶𝗿𝘀𝘁 𝗙𝗗𝗔-𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗱𝗿𝘂𝗴 𝗳𝗼𝗿 𝘁𝘆𝗽𝗲 𝗼𝗳 𝗮𝗴𝗴𝗿𝗲𝘀𝘀𝗶𝘃𝗲 𝗯𝗿𝗮𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 When Jazz Pharmaceuticals incoming CEO Renee Gala takes the reins at the drugmaker next week, she'll have a brand-new launch to manage. https://lnkd.in/gXE7VuBP
-
𝗢𝗿𝗯𝗶𝗠𝗲𝗱 𝗴𝗮𝘁𝗵𝗲𝗿𝘀 $𝟭.𝟴𝟲𝗕 𝗳𝗼𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗳𝘂𝗻𝗱 𝗱𝗲𝘀𝗽𝗶𝘁𝗲 '𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗶𝗻𝗴' 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗲𝗾𝘂𝗶𝘁𝘆 𝗺𝗮𝗿𝗸𝗲𝘁 Biotech backer OrbiMed has raised $1.86 billion in commitments for its fifth fund aimed at “growth-oriented healthcare companies.” https://lnkd.in/gySjtG7j
-
Luminary Group reposted this
We’re seeing a record number of CCO changes right now — what’s going on? At Luminary Group, we’re currently supporting 11 live Chief Commercial Officer (CCO) searches — the most we’ve ever had at one time. So, why are so many CCOs in transition? Here’s what we’re hearing from founders, boards, and investors: - Lack of a hands-on leadership style - Not client-facing enough - Limited emotional intelligence - Culture misalignment - Gaps in training and team development And here’s what CCOs themselves are saying - - No support from the CEO or leadership team for new ideas - Misalignment or lack of trust with private equity - Unclear expectations or shifting scope - No ability to shape or influence the culture - Constant changes to the business plan There’s no single reason, but the pattern is hard to ignore. What are you seeing? Get in touch for exclusive, live opportunities and lets have a confidential call. #leadership #executivesearch #lifesciences #privateequity #CCO #commercialleaders #culturefit #luminarygroup
-
-
𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝘁𝘆 𝗽𝗵𝗮𝗿𝗺𝗮 𝗦𝗘𝗥𝗕 𝘁𝗼 𝗯𝘂𝘆 𝗬-𝗺𝗔𝗯𝘀 𝗶𝗻 $𝟰𝟭𝟮𝗠 𝗮𝗹𝗹-𝗰𝗮𝘀𝗵 𝗱𝗲𝗮𝗹 Specialty drugmaker SERB Pharmaceuticals plans to buy cancer biotech Y-mAbs Therapeutics to further broaden its portfolio of more than 70 medicines … https://lnkd.in/ebPzeKE6
-
Recipharm, a leading global contract development and manufacturing organisation (CDMO), has announced the appointment of Neil Jones as its new Chief Commercial Officer. Neil brings over 25 years of experience in the pharmaceutical services sector, with a strong track record of delivering commercial growth and building high-performing, customer-focused teams across global markets. He officially joined Recipharm in August 2025. Prior to joining Recipharm, Neil Jones served as Chief Commercial Officer at Aenova Group, where he oversaw significant new business expansion and played a key role in the company’s successful sale. His previous leadership roles include senior commercial and operational positions at Catalent, as well as CEO of the UK’s Vaccines Manufacturing and Innovation Centre (VMIC), where he led the organisation through its acquisition. Throughout his career, Neil Jones has demonstrated a consistent ability to align commercial strategies with evolving customer needs, driving sustained growth across complex, international organisations. His leadership style is defined by a focus on collaboration, team empowerment, and results-oriented execution. He holds a BSc in Chemistry from the University of Bristol and a Postgraduate Certificate in Management from the University of the West of England. With this appointment, Recipharm strengthens its executive leadership team as it continues to expand its global footprint and enhance its service offering across the pharmaceutical value chain. #CDMO #PharmaceuticalIndustry #LifeSciences #PharmaLeadership #ExecutiveAppointment #Recipharm #CommercialExcellence #GlobalPharma #PharmaNews #PharmaGrowth #PharmaInnovation #NeilJones #PharmaBusiness #PharmaStrategy #ContractManufacturing
-
-
𝗔𝘀𝗮𝗵𝗶 𝗞𝗮𝘀𝗲𝗶 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝘁𝗼 𝗕𝘂𝗶𝗹𝗱 𝗡𝗲𝘄 𝗦𝗽𝗶𝗻𝗻𝗶𝗻𝗴 𝗣𝗹𝗮𝗻𝘁 𝗳𝗼𝗿 𝗩𝗶𝗿𝘂𝘀 𝗥𝗲𝗺𝗼𝘃𝗮𝗹 𝗙𝗶𝗹𝘁𝗲𝗿𝘀 Asahi Kasei Life Science will construct a new spinning plant for its Planova virus removal filters in Nobeoka City, Miyazaki, Japan. https://lnkd.in/epRNps4s
-
𝗔𝗹𝘁𝗼𝘀 𝗟𝗮𝗯𝘀 𝗵𝗶𝗿𝗲𝘀 𝗮 𝗻𝗲𝘄 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗰𝗵𝗶𝗲𝗳 𝘄𝗶𝘁𝗵 𝗺𝗧𝗢𝗥 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲, 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀 𝗰𝗵𝗼𝗽𝘀 Altos Labs the secretive anti-aging company with billions of dollars in funding, has a new chief medical officer to steer its clinical development. Joan Mannick https://lnkd.in/dR4SZ-cY
-
𝟰𝗗𝗠𝗧'𝘀 𝘀𝘁𝗼𝗰𝗸 𝗰𝗹𝗶𝗺𝗯𝘀 𝗮𝘀 𝗲𝘆𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗸𝗲𝗲𝗽 𝗷𝗲𝘁𝘁𝗶𝘀𝗼𝗻𝗶𝗻𝗴 𝗶𝗻𝗷𝗲𝗰𝘁𝗶𝗼𝗻𝘀 4D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema (DME) and sending its stock up more than 40% in premarket trading. https://lnkd.in/eS7p9YPz
-
𝗘𝗮𝘁𝗶𝗻𝗴 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿 𝘁𝗲𝗹𝗲𝗵𝗲𝗮𝗹𝘁𝗵 𝘀𝘁𝗮𝗿𝘁𝘂𝗽 𝗘𝗾𝘂𝗶𝗽 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟰𝟳𝗠 Virtual eating disorder treatment startup Equip has secured $47 million in new funding https://lnkd.in/ewQCJEgU